EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase IV)Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Ready‐to‐use abobotulinumtoxinA solution versus powder botulinumtoxinA for treatment of glabellar lines: Investigators' and subjects' experience in a Phase IV study

Priyanka Chadha, Peter Arne Gerber, Said Hilton, Beatriz Molina, Syed Haq, Jackie Partridge, Vincent Wong, Klaus Hoffmann, Cecilia Persson, Inna Prygova

Journal of Cosmetic Dermatology · 2024

DOI: 10.1111/jocd.16359 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2024. Verfasst von Priyanka Chadha und 9 weiteren Autor:innen. Beteiligte Einrichtung: Acquisition Aesthetics, London & Cavendish Clinic, London, UK. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Skin Aging, Powders, Patient Satisfaction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Galderma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Botulinum neurotoxin type A (BoNT‐A) is well‐established for treatment of glabellar lines (GLs), and mostly formulated as powders requiring reconstitution for injection. The approved liquid formulation, ready‐to‐use (RTU) abobotulinumtoxinA was developed to ease injection procedures and prevent reconstitution errors. This multicenter, open‐label, Phase IV study evaluated GL treatment experience using RTU abobotulinumtoxinA versus powder BoNT‐A (onabotulinumtoxinA).

Methods

Females with experience of BoNT‐A facial treatment were randomized 2:1 to GL treatment with 50 U RTU abobotulinumtoxinA ( N = 99) or 20 U powder BoNT‐A ( N = 51) and followed‐up for 6 months or 1 month, respectively. Assessments included: time to prepare each product for injection (primary endpoint); investigators' experience with product preparation/reconstitution; investigators' and subjects' treatment experience; safety; and for the RTU product: aesthetic improvement of GLs; subject satisfaction.

Results

Compared with powder BoNT‐A, RTU abobotulinumtoxinA required statistically significantly less preparation time (mean 0:33 vs. 1:34 min: s; p < 0.0001). Investigators preferred RTU abobotulinumtoxinA over powder BoNT‐A (81% of treatment sessions) and found it allowed more time to communicate with subjects (97%). All investigators (100%) also found it easy‐to‐use, easy‐to‐learn, and that it fulfilled their expectations. Subjects found the RTU abobotulinumtoxinA treatment comfortable (91%), and through 6 months posttreatment, most reported satisfaction with their appearance (≥88%), looking natural (≥95%) and refreshed (≥80%). At Month 1, 99% of RTU‐treated subjects had investigator‐assessed improved aesthetic appearance in GLs, maintained in 76% at Month 6. No serious adverse events occurred.

Conclusion

RTU abobotulinumtoxinA for GL treatment is well‐tolerated, efficacious, shows high levels of subject satisfaction throughout 6 months, saves time, and is preferred by clinicians over powder BoNT‐A. ClinicalTrials.gov Registry NCT05277337.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ASkin AgingPowdersPatient SatisfactionForeheadHumansFemaleAdultMiddle AgedNeuromuscular AgentsTreatment OutcomeCosmetic TechniquesAgedEstheticsSolutions

Stichwörter der Autor:innen

AlluzienceabobotulinumtoxinA solutionglabellar linesready‐to‐usesubject‐reported outcomes

Substanzen

Botulinum Toxins, Type AabobotulinumtoxinAPowdersNeuromuscular Agentsonabotulinum toxin ASolutions

Autor:innen und Institutionen

  • Acquisition Aesthetics, London & Cavendish Clinic, London, UK.
  • Dermatologie am Luegplatz and Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
  • Studienzentrum Privatpraxis Dr. Hilton & Partner, Düsseldorf, Germany.
  • Medikas Clinic, Medikas Medispa Ltd, Street, UK.
  • Haq Medical Consultancy and AM Aesthetics, London, UK.
  • The Aesthetic Consultancy, Edinburgh, UK.

Förderung

  • Galderma

Zitieren

APA

Chadha, P., Gerber, P. A., Hilton, S., Molina, B., Haq, S., Partridge, J., Wong, V., Hoffmann, K., Persson, C., & Prygova, I. (2024). Ready‐to‐use abobotulinumtoxinA solution versus powder botulinumtoxinA for treatment of glabellar lines: Investigators' and subjects' experience in a Phase IV study. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16359

Vancouver

Chadha P, Gerber PA, Hilton S, Molina B, Haq S, Partridge J, et al. Ready‐to‐use abobotulinumtoxinA solution versus powder botulinumtoxinA for treatment of glabellar lines: Investigators' and subjects' experience in a Phase IV study. Journal of Cosmetic Dermatology. 2024. doi:10.1111/jocd.16359

BibTeX
@article{Chadha2024,
  author = {Chadha, Priyanka and Gerber, Peter Arne and Hilton, Said and Molina, Beatriz and Haq, Syed and Partridge, Jackie and Wong, Vincent and Hoffmann, Klaus and Persson, Cecilia and Prygova, Inna},
  title = {Ready‐to‐use abobotulinumtoxinA solution versus powder botulinumtoxinA for treatment of glabellar lines: Investigators' and subjects' experience in a Phase IV study},
  journal = {Journal of Cosmetic Dermatology},
  year = {2024},
  doi = {10.1111/jocd.16359}
}
Kostenlos starten →